Search Prime Grants

W81XWH2210762

Project Grant

Overview

Grant Description
Combination of HBV immunotherapy with shRNA-mediated PD-1/PDL checkpoint inhibition for treatment of chronic HBV.
Awardee
Carogen
Funding Goals
PEER REVIEWED MEDICAL RESEARCH PROGRAM AWARD MECHANISM: TECHNOLOGY/THERAPEUTIC DEVELOPMENT AWARD - FUNDING LEVEL 2
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Hamden, Connecticut 065183025 United States
Geographic Scope
Single Zip Code
Related Opportunity
W81XWH21PRMRPTTDA
Analysis Notes
Amendment Since initial award the End Date has been extended from 09/14/25 to 09/14/26.
Carogen was awarded HBV Immunotherapy with shRNA-PD-1/PDL for Chronic HBV Project Grant W81XWH2210762 worth $5,515,484 from Defense Health Agency in September 2022 with work to be completed primarily in Hamden Connecticut United States. The grant has a duration of 4 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 12/18/25

Period of Performance
9/15/22
Start Date
9/14/26
End Date
86.0% Complete

Funding Split
$5.5M
Federal Obligation
$0.0
Non-Federal Obligation
$5.5M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to W81XWH2210762

Transaction History

Modifications to W81XWH2210762

Additional Detail

Award ID FAIN
W81XWH2210762
SAI Number
None
Award ID URI
None
Awardee Classifications
Small Business
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
JNMNVKEUU2Y3
Awardee CAGE
6TGS8
Performance District
CT-03
Senators
Richard Blumenthal
Christopher Murphy

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $5,155,484 100%
Modified: 12/18/25